GLP-1s are not the iPhone of metabolic health. They are the modem: the technology connecting millions of people to a much larger operating system for health.
I spent yesterday in London representing LifeX at the inaugural Metabolic Health Business Building Summit, co-hosted by the McKinsey Health Institute and Stanford Medicine.
The room included executives from pharmaceutical companies, consumer-goods giants, insurers, researchers, physicians, founders and investors: more than 70 people from over 50 organizations.
On paper, it had the ingredients of a conference where everyone agrees that an important problem is important.
It turned out to be much more interesting than that.
The conversation was not really about obesity.
It was not even really about healthcare.
It was about the emergence of what I increasingly think is a new economic sector.
The Pattern
Every few decades, a problem or technology graduates from being a specialist category into an organizing principle.
Computers stopped being “data processing.”
The Internet stopped being “telecommunications.”
Artificial intelligence stopped being a branch of software.
Each became a horizontal platform that reorganized many industries at once.
I think metabolic health is beginning a similar transition.
Today we still understand it primarily through medical categories: obesity, diabetes, cardiovascular disease, endocrinology and, most recently, GLP-1 drugs.
That is how platforms often look before they escape their original category.
The Wrong Question
Much of the investment conversation is currently organized around questions like:
- Which GLP-1 will win?
- Who will develop the best obesity drug?
- Which pharmaceutical company gains market share?
These are reasonable questions.
They may also be much too small.
The more interesting question is:
What happens after hundreds of millions of people become actively engaged in managing their metabolic health?
That is a completely different market.
GLP-1s matter not simply because they treat obesity, but because they have made metabolism visible, actionable and commercially legible.
They have converted a previously amorphous problem into something consumers, doctors, employers and investors believe can be changed.
But the drug market may be only the opening act.
The Metabolic Health Stack
Once you ask the larger question, you discover that the opportunity extends far beyond pharmaceuticals.
Imagine the stack.
1. Data and diagnostics
Continuous glucose monitors, wearables, laboratory testing, imaging, genomics, microbiome data and other sensors make the body increasingly measurable.
2. Intelligence
AI systems interpret thousands of biological and behavioral signals, recognize patterns and recommend interventions.
3. Behavior and intervention
Nutrition, exercise, sleep, stress management, medication, coaching, habit formation and social reinforcement become coordinated rather than fragmented.
4. Commerce and incentives
Food, supplements, insurance, employer benefits, financial incentives, travel, hospitality and consumer products adapt around the objective of producing better health.
Every layer becomes programmable.
Every layer becomes investable.
And every layer begins to communicate with the others.
That is not merely a healthcare market.
It is an operating system.
Prevention Finally Gets a Business Model
For decades, everyone in healthcare has repeated the same sentence:
“We should focus more on prevention.”
Everyone nodded.
Almost nobody built a durable business around it.
Traditional healthcare economics reward procedures, prescriptions and episodes of illness. The customer arrives after something has gone wrong.
Prevention promises to prevent the revenue-generating event.
Metabolic health may finally change that equation because several forces are arriving at once:
- AI is reducing the cost of individualized guidance.
- Sensors are making continuous biological measurement affordable.
- Consumers increasingly want agency over their health.
- GLP-1s have created mass awareness of metabolism.
- Employers and insurers can increasingly measure the economic value of intervention.
Prevention is no longer merely morally attractive.
It may become economically superior.
That changes everything.
Healthcare’s Strangest Business Model
Healthcare may be the first multitrillion-dollar industry whose customers actively hope never to use it.
You do not wake up eager to visit a hospital.
You do not develop a daily relationship with your MRI machine.
You do not recommend your colonoscopy to friends with the enthusiasm reserved for a restaurant, a phone or a hotel.
Metabolic health flips this relationship.
Health becomes something a person interacts with every day, not once a year and not only after diagnosis.
In that sense, the best analogy may not be oncology or cardiology.
It may be financial technology.
People do not wait for bankruptcy before checking their bank balance. They continuously monitor their financial lives, receive recommendations and modify their behavior.
The same thing is beginning to happen with biology.
AI Changes the Equation
Every human metabolism is different.
People respond differently to food, sleep, stress, exercise and medication. Context matters. Timing matters. Combinations matter.
Historically, deep personalization was expensive because expert human attention does not scale.
AI changes the marginal cost of interpretation.
Imagine an intelligent health companion that understands your laboratory values, wearable data, medications, sleep, genetics, calendar, travel schedule, grocery purchases, exercise history, family history and behavioral patterns.
Not a chatbot that occasionally reminds you to eat vegetables.
An agent that notices your sleep deteriorating, understands that you have crossed six time zones, adjusts your exercise plan, modifies meal timing, checks a medication interaction, orders an appropriate test and closes the loop afterward.
Healthcare has always suffered from scarcity: too few doctors, too little time and too much fragmented information.
AI introduces the possibility of abundance.
The Real Prize
At LifeX, we invest at the intersection of AI, biology and health.
What made the McKinsey summit especially interesting was how clearly the metabolic-health opportunity now spans all three.
The next trillion-dollar companies in health may not resemble traditional healthcare companies.
Some will develop breakthrough therapeutics.
Some will build measurement and diagnostic infrastructure.
Some will become trusted consumer brands.
Others will own the intelligence layer, the engagement layer or the economic coordination layer.
History suggests that platform shifts rarely produce only one winner.
The personal computer produced Microsoft, Apple, Intel, Adobe, Dell and Oracle.
The smartphone produced Apple, Google, Qualcomm, Uber, Airbnb, DoorDash and Shopify.
Platforms create ecosystems.
Metabolic health increasingly feels like the beginning of another one.
A Prediction
Ten years from now, we may laugh at the fact that metabolic health was once classified as a medical specialty.
It will shape food, insurance, employment, education, urban design, consumer products, hospitality, longevity and artificial intelligence.
It may even affect national competitiveness.
A population that remains healthier for longer is not merely happier. It is more productive, less expensive to support and better able to adapt to an aging society.
The winners will not simply help people lose weight.
They will help people make better biological decisions every day.
That is a much larger opportunity.
Thanks to Hemant Ahlawat, Lloyd Minor, the McKinsey Health Institute, Stanford Medicine and everyone who participated in an unusually thoughtful discussion.
Conferences rarely change my mind.
This one did something more useful: it strengthened a conviction that has been forming for several years.
Metabolic health is escaping healthcare.
When that happens, entirely new categories of companies become possible.
Those are usually the most interesting moments to invest.
Related reading
- How Ozempic Works—and What Else Could Revolutionize Metabolic Health
https://amol.sarva.co/podcast/how-ozempic-works-and-what-else-could-revolutionize-metabolic-health-with-james-peyer-of-cambrian-bio/ - Food as Medicine
https://amol.sarva.co/podcast/food-as-medicine-with-physician-and-founder-jeff-alfonsi/ - Life Extension
https://amol.sarva.co/life-extension/ - Sergey Young on Living Forever and Growing Young
https://amol.sarva.co/podcast/1-longevity-vc-sergey-young-on-living-forever-and-his-book-growing-young/
You must be logged in to post a comment.